Vitamin D receptor activation: Cardiovascular and renal implications

Kidney International Supplements

Volumn 3, Issue 5, 2013, Pages 427-430

  Nigwekar, Sagar U ^a   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic kidney disease; End stage renal disease; Hypertension; Left ventricular hypertrophy; Vitamin D; Vitamin D binding protein

Indexed keywords

VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

BLOOD PRESSURE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; HEART; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN METABOLISM;

EID: 84896714206     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2013.89     Document Type: Review

References (32)

1. Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 2012; 60: 139-156.
2. Holick MF. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. Bone 1995; 17: 107S-111S.
3. Weishaar RE, Kim SN, Saunders DE et al. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258: E134-E142.
4. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest 1987; 79: 1706-1712.
5. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
6. Chen S, Law CS, Grigsby CL et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011; 124: 1838-1847.
7. Wu J, Garami M, Cheng T et al. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588.
8. Wong MS, Delansorne R, Man RY et al. Chronic treatment with vitamin D lowers arterial blood pressure and reduces endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2010; 299: H1226-H1234.
9. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815.
10. Bae S, Singh SS, Yu H et al. Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction. J Appl Physiol 2013; 114: 979-987.
11. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519.
12. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
13. Nigwekar SU, Bhan I, Turchin A et al. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol 2013; 37: 325-332.
14. Kokot F, Pietrek J, Srokowska S et al. 25-Hydroxyvitamin D in patients with essential hypertension. Clin Nephrol 1981; 16: 188-192.
15. Burgaz A, Orsini N, Larsson SC et al. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2011; 29: 636-645.
16. Pilz S, Marz W, Wellnitz B et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93: 3927-3935.
17. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
18. Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382.
19. Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024-1032.
20. UMIN-CTR Clinical Trial (Accessed 7 August 2013, at upload.umin.ac.jp ).
21. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 1989; 10: 232-274.
22. Bhan I, Powe CE, Berg AH et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012; 82: 84-89.
23. Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-188.
24. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet 1986; 72: 281-293.
25. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
26. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
27. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
28. Pittas AG, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152: 307-314.
29. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
30. de Borst MH, Hajhosseiny R, Tamez H et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic Review. J Am Soc Nephrol 2013 (epub ahead of print).
31. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.
32. Tamez H, Zoccali C, Packham D et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012; 164: 902-909 e2.